Therefore, we investigated whether naturally occurring TCR from 19305DP without affinity enhancement could transfer high-avidity recognition of cancer cells to donor CD4+ T cells in addition to CD8+ T cells by retroviral TCR gene-engineering. The gene discussed is CD8A; the disease is cancer.